Singapore, Singapore

Joly Sukumaran

This inventor holds 37 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 6 EPO patents, primarily in Biocatalysis Engineering. Top assignee: Codexis, Inc.. Active years: 2013-2025.

USPTO Granted Patents = 37 

% Patents Active = 100.0


 

Average Co-Inventor Count = 8.5

ph-index = 8

Forward Citations = 167(Granted Patents)


Location History:

  • The Galen, SG (2013)
  • Singapore, SG (2014 - 2024)

Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Imine Reductases
LovD Polypeptides
Acyltransferase
Biocatalysis
Nucleic Acids
Carbapenem Synthesis
Reductive Amination
Biocatalytic Process
Eslicarbazepine
Engineered Biocatalysts
Polynucleotides
Variant Polypeptides
37 patents (USPTO):Explore Patents

Title: The Innovative Journey of Joly Sukumaran

Introduction: Joly Sukumaran, a pioneering inventor from Singapore, SG, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents: Joly Sukumaran's latest patents include a cutting-edge AI-powered healthcare device and a sustainable energy solution that have garnered international acclaim for their ingenuity.

Career Highlights: With a career spanning over two decades, Joly Sukumaran has established herself as a leading figure in the tech industry, holding multiple patents and receiving prestigious awards for her innovative work.

Collaborations: Throughout her career, Joly Sukumaran has collaborated with top research institutions, universities, and tech companies to further develop and implement her inventions, showcasing her ability to work across disciplines for the greater good.

Conclusion: Joly Sukumaran's relentless pursuit of innovation and her passion for creating solutions to real-world problems have solidified her reputation as a trailblazing inventor in the global tech landscape.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…